Interventional Lung Solutions Market Report 2026

The interventional lung solutions market size has grown strongly in recent years. It will grow from $2.47 billion in 2025 to $2.68 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing prevalence of copd and lung cancer, limitations of surgical lung interventions, advancements in bronchoscopy technology, growing hospital adoption of minimally invasive procedures, rising healthcare expenditure.

The interventional lung solutions market size is expected to see strong growth in the next few years. It will grow to $3.66 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to growth in aging population with respiratory diseases, increasing adoption of robotic-assisted interventions, expansion of outpatient pulmonary procedures, rising focus on early lung cancer diagnosis, technological advancements in navigation bronchoscopy. Major trends in the forecast period include rising adoption of minimally invasive pulmonary procedures, increasing use of robotic bronchoscopy systems, growing demand for lung volume reduction devices, expansion of image-guided interventional lung therapies, increasing preference for disposable bronchoscopes.

The rising prevalence of respiratory diseases is expected to drive the growth of the interventional lung solutions market in the coming years. Respiratory diseases encompass medical conditions that affect the lungs and airways, impairing normal respiratory function and making breathing difficult. The increase in these diseases is largely attributed to higher levels of air pollution, which lead to chronic exposure to harmful airborne particles and irritants. Interventional lung solutions assist in managing respiratory diseases by offering minimally invasive procedures that enhance lung function and alleviate symptoms in patients with chronic pulmonary conditions. For example, in May 2025, according to BioMed Central Ltd, a UK-based journal platform, the global prevalence of chronic obstructive pulmonary disease (COPD) is estimated at 10.3%, with the number of affected individuals projected to reach 600 million by 2050. Asthma currently impacts approximately 262 million people worldwide. Consequently, the growing prevalence of respiratory diseases is fueling the interventional lung solutions market.

Major companies in the interventional lung solutions market are focusing on developing advanced technologies, such as the Ion Endoluminal System, to enhance the accuracy of lung cancer diagnostics, support minimally invasive procedures, and improve patient outcomes through precise navigation and biopsy capabilities. The Ion Endoluminal System is a robotic-assisted platform designed for minimally invasive lung procedures, allowing accurate airway navigation to access small or hard-to-reach lung nodules. For example, in April 2024, H. Lee Moffitt Cancer Center and Research Institute Foundation Inc., a US-based non-profit organization, launched a new Ion Robotic Bronchoscopy platform, advancing their interventional pulmonology program with sophisticated fiber-optic technology and a minimally invasive catheter system. This system utilizes fiber optics and the smallest catheter available to reach all regions of the lung. It features an ultra-thin, highly flexible catheter with 180° articulation, integrated real-time vision, and shape-sensing technology, enabling precise navigation and biopsy of peripheral lung nodules that are difficult to access. The platform provides exceptional stability and accuracy for tissue sampling, allowing physicians to reach all 18 lung segments and supporting earlier detection of lung cancer.

In February 2025, Stryker Corporation, a US-based medical device company, acquired Inari Medical Inc. for an undisclosed amount. Through this acquisition, Stryker aims to expand its interventional endovascular portfolio by adding innovative, thrombolytic-free solutions for venous thromboembolism (VTE), including treatments for pulmonary embolism and deep vein thrombosis. Inari Medical Inc. is a US-based company specializing in interventional solutions for pulmonary conditions, with a particular focus on pulmonary embolism (PE) treatment.

Major companies operating in the interventional lung solutions market are Johnson and Johnson, Siemens AG, Medtronic plc, FUJIFILM Holdings Corporation, GE Healthcare Technologies Inc., Boston Scientific Corporation, Olympus Corporation, Intuitive Surgical Inc., Smiths Medical Inc., Cook Medical Inc., Merit Medical Systems Inc., Penumbra Inc., Vygon SA, AngioDynamics Inc., Vapotherm Inc., Pulmonx Corporation, Broncus Medical Inc., Thirona B.V., Body Vision Medical Ltd., EndoMed Systems GmbH.

North America was the largest region in the interventional lung solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interventional lung solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interventional lung solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the interventional lung solutions market by raising costs for imported medical devices, imaging components, and robotic surgical systems. These impacts are most pronounced in bronchoscopy equipment and robotic-assisted technologies, particularly across North America, Europe, and Asia-Pacific where device manufacturing is globally integrated. Increased tariffs have led to higher procurement costs for hospitals and specialty clinics. Positively, tariffs have driven local manufacturing initiatives and accelerated innovation in cost-efficient interventional lung devices.

The interventional lung solutions market research report is one of a series of new reports that provides interventional lung solutions market statistics, including interventional lung solutions industry global market size, regional shares, competitors with a interventional lung solutions market share, detailed interventional lung solutions market segments, market trends and opportunities, and any further data you may need to thrive in the interventional lung solutions industry. This interventional lung solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interventional lung solutions refer to minimally invasive procedures and technologies used to diagnose and treat lung conditions such as chronic obstructive pulmonary disease (COPD), lung cancer, and emphysema. These solutions commonly include bronchoscopy interventions, endobronchial valves, and image-guided therapies that enhance lung function and improve patient outcomes.

The primary product types of interventional lung solutions include bronchoscopes, endobronchial ultrasound needles, pleuroscopes, airway stents, and other related devices. Bronchoscopes are medical instruments used to visualize and examine the airways and lungs, typically inserted through the nose or mouth to diagnose and treat respiratory conditions. Technologies linked with bronchoscopes include robotic surgery, laser therapy, and electromagnetic navigation bronchoscopy. The procedures performed include bronchoscopy, thoracoscopy, pleuroscopy, and others. These solutions are applied in lung cancer treatment, COPD management, and sleep apnea therapy and are utilized by hospitals, ambulatory surgical centers, specialty clinics, and other healthcare facilities.

The interventional lung solutions market consists of revenues earned by entities by providing services such as endobronchial valve placement, navigational bronchoscopy, lung volume reduction, and airway stenting. The market value includes the value of related goods sold by the service provider or included within the service offering. The interventional lung solutions market also consists of sales of products including bronchial thermoplasty devices, cryotherapy devices, bronchial stents, and biopsy forceps. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.